You are here: Home » Markets » News
Business Standard

Sun Pharma slips 9% as Daiichi Sankyo exits. Should you buy?

A combined 276.63 million shares representing 11.5% of total equity of Sun Pharma changed hands on the NSE and BSE

Puneet Wadhwa & Deepak Korgaonkar  |  New Delhi / Mumbai 

Shares of Sun Pharmaceutical Industries ended down 9% at Rs 952 on the National Stock Exchange (NSE) after Japanese pharmaceutical company, Daiichi Sankyo, sold its stake in the company via an open market transaction.

A combined 276.63 million shares representing 11.5% of total equity of Sun Pharma changed hands on the counter on the NSE and BSE.

According to reports, Daiichi Sankyo planned to sell its entire 8.9% stake (214.96 million equity shares) in Sun Pharmaceuticals in block deals in the stock market on Tuesday. CLICK HERE TO READ THE FULL REPORT

Reports suggest that the shares were to be be sold at a discount of 0% to 10.9%, which would be a price range of Rs 930 to Rs 1,043.80 per share. Goldman Sachs was the sole book runner for the deal.

In June 2008, Daiichi-Sankyo had acquired 63.92% stake in Ranbaxy from in a deal worth $ 4.6 billion (Rs 737 per share). In April 2014, Sun Pharma had acquired Ranbaxy in a shares swap deal. As per the terms of agreement, shareholders in Ranbaxy, including Daiichi Sankyo, had received 0.8 Sun Pharma share for each share of Ranbaxy.

But what explains the fall in the stock and is it a good opportunity to buy the counter?

Explains Sarabjit Kour Nangra, vice-president for pharma research at Angel Broking: “The stock has reacted negatively since the shares would have been sold at significantly lower price, as compared to the previous closing price of the stock. This transaction does not change anything materially for the company. The fall does present a good opportunity for investors to buy the stock.”

Surajit Pal, senior research analyst – institutional equities at Prabhudas Lilladher also suggests that the transaction merely changes the shareholding pattern for the company. Sun Pharma, according to him, still remains on a strong footing.

“Till now, the company has been guiding fine. Going ahead, we need to see how fast they can turn around Ranbaxy and that should be the near – term challenge for Sun Pharma. Its performance in the US is also fine. Sun has given a guidance of $250 million to $300 million in synergy in the next three years from Ranbaxy, of which one-third I believe will come in due to tax benefits. So in all, the company remains on a strong footing.”

Analysts at ICICI Securities, too, have reiterated a 'buy' recommendation on the stock. "Post offloading, the stock has corrected around 10% and is down nearly around 20% from it’s all time high. This has provided an ideal opport unity to re-enter the stock. We will revisit our target price post Q4 results as we will have financials of the combined entity. We maintain our target price of Rs 1036 i.e. 26x FY17E EPS of Rs 39.8," said Siddhant Khandekar, Mitesh Shah and Nandan Kamat in a note.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, April 21 2015. 15:35 IST